What can we help you find?
Matthew Johnson, MD, and Paul Dobesh, PharmD, FCCP, BCPS, share some final thoughts on the dosing of DOACs in obese patients.
The panel of experts review the monitoring parameters for determining efficacy of DOACs.
Experts discuss the recommendation in monitoring when using DOACs.
The panel of experts in cardiology discuss the barriers with treatment of obese patients with DOACs. They also discuss the importance of education of their peers.
Experts in cardiovascular disease discuss the lack of data supporting dose adjustment of DOACs because of weight.
Paul Dobesh, PharmD, FCCP, BCPS, discusses the data regarding the use of DOACs in obese patients with VTE.
Paul Dobesh, PharmD, FCCP, BCPS, shares data from several studies looking at the use of DOACs in the obese population.
The panel discusses the risks and benefits of warfarin in the use of thrombosis.
The panel of experts in cardiology share their insights and the implications of the ISTH 2016 statement for DOACs.
Paul Dobesh, PharmD, FCCP, BCPS, reviews the ISTH 2016 statement regarding the avoidance of DOACs in the obese population.
Experts in cardiovascular disease review the definition of obesity and morbid obesity as stated by the CDC. They provide some insights on the management of thrombosis risks.
Paul Dobesh, PharmD, FCCP, BCPS, discusses the dosing differences among the DOAC agents.